Kidney cancer: Past, present, and future

被引:21
作者
Novick, Andrew C. [1 ]
机构
[1] Cleveland Clin Fdn, Glickman Urol Inst, Cleveland, OH 44195 USA
关键词
D O I
10.1016/j.urolonc.2007.03.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:188 / 195
页数:8
相关论文
共 41 条
[31]   Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [J].
Motzer, RJ ;
Michaelson, MD ;
Redman, BG ;
Hudes, GR ;
Wilding, G ;
Figlin, RA ;
Ginsberg, MS ;
Kim, ST ;
Baum, CM ;
DePrimo, SE ;
Li, JZ ;
Bello, CL ;
Theuer, CP ;
George, DJ ;
Rini, BI .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :16-24
[32]   Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].
Motzer, Robert J. ;
Hutson, Thomas E. ;
Tomczak, Piotr ;
Michaelson, M. Dror ;
Bukowski, Ronald M. ;
Rixe, Olivier ;
Oudard, Stephane ;
Negrier, Sylvie ;
Szczylik, Cezary ;
Kim, Sindy T. ;
Chen, Isan ;
Bycott, Paul W. ;
Baum, Charles M. ;
Figlin, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124
[33]   LONG-TERM FOLLOW-UP AFTER PARTIAL REMOVAL OF A SOLITARY KIDNEY [J].
NOVICK, AC ;
GEPHARDT, G ;
GUZ, B ;
STEINMULLER, D ;
TUBBS, RR .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (15) :1058-1062
[34]   Nephron-sparing surgery for renal cell carcinoma [J].
Novick, AC .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :393-407
[35]   EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON NEPHROPATHY IN PATIENTS WITH A REMNANT KIDNEY [J].
NOVICK, AC ;
SCHREIBER, MJ .
UROLOGY, 1995, 46 (06) :785-789
[36]   Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience [J].
Patard, JJ ;
Shvarts, O ;
Lam, JS ;
Pantuck, AJ ;
Kim, HL ;
Ficarra, V ;
Cindolo, L ;
Han, KR ;
De la Taille, A ;
Tostain, J ;
Artibani, W ;
Abbou, CC ;
Lobel, B ;
Chopin, DK ;
Figlin, RA ;
Mulders, PFA ;
Belldegrun, AS .
JOURNAL OF UROLOGY, 2004, 171 (06) :2181-2185
[37]   Long-term survival analysis after laparoscopic radical nephrectomy [J].
Permpongkosol, S ;
Chan, DY ;
Link, RE ;
Sroka, M ;
Allaf, M ;
Varkarakis, I ;
Lima, G ;
Jarrett, TW ;
Kavoussi, LR .
JOURNAL OF UROLOGY, 2005, 174 (04) :1222-1225
[38]   Initial evaluation of Cyberknife technology for extracorporeal renal tissue ablation [J].
Ponsky, LE ;
Crownover, RL ;
Rosen, MJ ;
Rodebaugh, RF ;
Castilla, EA ;
Brainard, J ;
Cherullo, EE ;
Novick, AC .
UROLOGY, 2003, 61 (03) :498-501
[39]   A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma [J].
Sorbellini, M ;
Kattan, MW ;
Snyder, ME ;
Reuter, V ;
Motzer, R ;
Goetzl, M ;
McKiernan, J ;
Russo, P .
JOURNAL OF UROLOGY, 2005, 173 (01) :48-51
[40]   A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].
Yang, JC ;
Haworth, L ;
Sherry, RM ;
Hwu, P ;
Schwartzentruber, DJ ;
Topalian, SL ;
Steinberg, SM ;
Chen, HX ;
Rosenberg, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434